ACL Shares Australian Clinical Labs Limited
ASX · ASXLast in our picks 2026-10-23 — not in the current list; analysis below is from that screen
Positive annual performance and diagnostics recovery offer improving earnings momentum at an investable scale.
Future value: $2.79 (-4.63%) · 6-12 months · analyst consensus
Signal breakdown
- ▸15.4% annual gain and positive sector momentum
- ▸Above 50-day MA (+3.42%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 1.84× average — accumulation
- ▸Near 52-week high (91.6% of range) — strength
- ▾Trading above its price target — limited upside
Is ACL a buy right now?
Trend: ACL is trading above the 50-day average (+4.23%), RSI 33 — neutral momentum, with a 3-month return of +24.37%.
Valuation & quality: Australian Clinical Labs Limited trades on a trailing P/E of 24.7, forward P/E 14.5, price-to-book 3.66; fundamentals show net margin 3.2%, return on equity 14.9%, revenue growth -0.4% year on year.
Analyst consensus: 7 analysts have a mean 12-month price target of A$2.79 (-5.6% vs the last close; range A$2.26 – A$3.65), consensus rating “none”.
Income: trailing dividend yield 4.36%.
Our screen: BUY (score 3) — Positive annual performance and diagnostics recovery offer improving earnings momentum at an investable scale.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -9.70% | -7.40% | +7.40% | +10.30% | +6.20% | +16.80% | +2.50% | +3.90% |
Fundamentals
Analyst price target
Technical signals
About Australian Clinical Labs Limited
Australian Clinical Labs Limited provides pathology diagnostic services in Australia.
Sector: Healthcare · Industry: Diagnostics & Research · Australia · 4,500 employees · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.